BioSpace News Archive

Generate Biomedicines today announced that Jane Mendillo has been appointed to its board of directors.

US Nuclear’s (OTC-QB: UCLE) strategic partner Pulmostics Ltd is a biotech start-up devoted to early screening women for breast cancer using innovative breath analysis technology that proved to be a fast, economical, painless non-invasive system to screen for breast cancer and other cancers.

NLS Pharmaceutics Ltd. today announced that it has entered into a definitive agreement with BVF Partners L.P. to raise aggregate gross proceeds of up to $30.0 million in a two-tranche private placement.

SciSparc Ltd. today announced positive results from its study of SCI-210 on Status Epilepticus (“SE”), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, which reaffirm the potential of its proprietary combination products to have a positive effect while minimizing adverse side effects.

X4 Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock at a price to the public of $1.10 per share and accompanying Class C warrant.

Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces that it has received feedback from the FDA following a pre-Investigational New Drug (pre-IND) interaction regarding the development pathway to a Phase 1 clinical trial of QN-302 for the treatment of G4-targeted advanced solid tumors.

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the company’s EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

Inizio, a strategic partner for companies in health and life sciences, has today announced the acquisition of Evolution Road, a digital innovation company in life science omnichannel, digital marketing and digital health strategy.

ANEW MEDICAL, INC. (“ANEW” or “the Company”) (OTCPK:LEAS), a medical technology holding company announced that it has acquired an exclusive worldwide license from Universitat Autonomous de Barcelona (UAB) and affiliated institutions to a platform technology for discovery and development of cell and gene therapy products based on a proprietary human protein and gene called α-Klotho.